Loading...
•
Jun 30, 2021
Sage Q2 2021 Earnings Report
Sage's pipeline advanced with positive topline data from the WATERFALL Study and continued expansion across brain health franchises.
Key Takeaways
Sage Therapeutics reported positive topline data from the pivotal WATERFALL Study of zuranolone in patients with MDD, showing a statistically significant and clinically meaningful reduction in depressive symptoms. The company is advancing its pipeline, including the initiation of Phase 1 program for SAGE-689 and first patient dosed in SAGE-718 PARADIGM Parkinson’s disease Study Part B. Net revenue from sales of ZULRESSO was $1.6 million.
WATERFALL Study of zuranolone in MDD patients met primary endpoint with statistically significant reduction in depressive symptoms.
Pipeline expansion continued with advancement of brain health franchises and initiation of Phase 1 program for SAGE-689.
First patient dosed in SAGE-718 PARADIGM Parkinson’s disease Study Part B.
Updated enrollment guidance for Phase 3 SKYLARK Study of zuranolone in PPD, with topline data expected mid-2022.
Forward Guidance
Sage anticipates having cash, cash equivalents, and marketable securities of more than $1.7 billion at the end of 2021 and does not anticipate receipt of any milestone payments from collaborations in 2021.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...